PA
TSHA icon

Profund Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Profund Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546K Sell
80,200
-54,471
-40% -$322K 0.02% 530
2026
Q1 		$602K Buy
134,671
+6,081
+5% +$28.3K 0.02% 485
2025
Q4 		$707K Buy
128,590
+75,224
+141% +$365K 0.02% 447
2025
Q3 		$175K Buy
53,366
+26,767
+101% +$75.8K 0.01% 1004
2025
Q2 		$61.4K Buy
+26,599
New +$57.8K ﹤0.01% 984
2025
Q1 		– Sell
-50,242
Closed -$86.9K – 1111
2024
Q4 		$86.9K Buy
+50,242
New +$104K ﹤0.01% 1079

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Profund Advisors's TSHA Position: Q2 2026 in Review

Profund Advisors reduced its Taysha Gene Therapies (TSHA) stake by 40% in Q2 2026, selling an estimated $322K and leaving 80,200 shares worth $546K. The position accounts for 0.02% of the portfolio, ranked #530.

Profund Advisors first reported a position in TSHA in Q4 2024 and has held it in 6 quarters since. The position peaked at $707K in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Profund Advisors held 80,200 shares of Taysha Gene Therapies worth $546K as of Q2 2026.
  • Profund Advisors sold 54,471 Taysha Gene Therapies shares in Q2 2026, an estimated $322K.
  • Taysha Gene Therapies made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #530 holding.
  • Profund Advisors first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 6 quarters since.
  • Profund Advisors's Taysha Gene Therapies position peaked at $707K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.